KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER

Clinical trials for KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER trials appear

Sign up with your email to follow new studies for KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Breakthrough trial targets 'Undruggable' lung cancer mutations

Disease control Recruiting now

This clinical trial is testing several new experimental drugs designed to target specific genetic mutations (called RAS mutations) found in advanced non-small cell lung cancer. The study will involve 616 adults whose cancer has progressed despite standard treatments. Researchers …

Matched conditions: KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER

Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control

Last updated Mar 09, 2026 14:23 UTC

KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER

Get alerted when new KRAS G12C-MUTATED SOLID TUMORS, LUNG CANCER trials appear

Breakthrough trial targets 'Undruggable' lung cancer mutations